梅花生物科技集团股份有限公司关于以集中竞价交易方式回购公司股份的进展公告

Group 1 - The company has approved a share repurchase plan with a total amount between RMB 300 million and RMB 500 million, aimed at reducing registered capital [2] - As of the end of July 2025, the company has repurchased 35,708,400 shares, accounting for 1.25% of the total share capital, with a total expenditure of RMB 352,024,400 [3] - The repurchase was conducted at a minimum price of RMB 9.10 per share and a maximum price of RMB 10.68 per share, complying with relevant regulations [3] Group 2 - The company has completed its 2025 employee stock ownership plan, purchasing a total of 21,042,422 shares, which is 0.74% of the total share capital, at an average price of approximately RMB 10.70 per share [7][8] - The total amount spent on the employee stock ownership plan was RMB 225,143,665.20 [7] - The purchased shares will be locked for a period of 12 to 24 months, with a release schedule of 50% after each lock-up period [8]